Metopirone 250 mg capsules/cormeto    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
75Cushing disease1

75. Cushing disease    [ 191 clinical trials,   172 drugs,   (DrugBank: 48 drugs),   61 drug target genes,   121 drug target pathways]
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 191 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-000162-22-IT
(EUCTR)
19/03/201525/11/2014Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment periodProspective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Metopirone 250 mg capsules/Cormeto
Product Name: metyrapone
INN or Proposed INN: METYRAPONE
Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes
70Phase 4United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden